论文部分内容阅读
目的:探讨黄葵胶囊联合缬沙坦治疗糖尿病肾病(DN)的临床效果及对缺氧诱导因子-1α(HIF-1α)和血管内皮生长因子(VEGF)水平的影响。方法:选取2015年1月至2015年12月就诊的124例DN患者,根据随机数字表将患者分为观察组(n=62)和对照组(n=62),两组患者入组后积极控制血糖,并给予降糖药物治疗。对照组在控糖基础上应用缬沙坦口服治疗,观察组在对照组基础上应用黄葵胶囊口服治疗,比较两组患者治疗前后肾功能指标、炎症因子水平及血清HIF-1α、VEGF水平变化。结果:观察组治疗后FBG、Hb A1c、TG、TC、LDL-C、Scr、BUN、24h UAER、血清Cys-C水平显著低于对照组(P<0.05),HDL-C水平显著高于对照组(P<0.05)。观察组治疗后HIF-1α和VEGF水平显著低于对照组(P<0.05)。结论:黄葵胶囊联合缬沙坦能有效提高DN患者治疗效果,改善患者肾功能,其机制可能与抑制DN患者HIF-1α、VEGF水平有关。
Objective: To investigate the clinical effects of huang kui capsule combined with valsartan in the treatment of diabetic nephropathy (DN) and its effect on the level of hypoxia inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF). Methods: A total of 124 patients with DN who were treated from January 2015 to December 2015 were enrolled. Patients were divided into observation group (n = 62) and control group (n = 62) according to random number table. Both groups were active Control blood sugar, and give hypoglycemic drugs. The control group was given valsartan oral treatment on the basis of sugar control. The observation group was treated with Huang Kui capsule on the basis of the control group. The changes of renal function index, inflammatory cytokines and serum HIF-1α and VEGF levels before and after treatment were compared between two groups . Results: The levels of FBG, Hb A1c, TG, TC, LDL-C, Scr, BUN, 24h UAER and serum Cys-C in the observation group were significantly lower than those in the control group (P < Group (P <0.05). The levels of HIF-1α and VEGF in the observation group were significantly lower than those in the control group (P <0.05). Conclusion: Huang Kui capsule combined with valsartan can effectively improve the therapeutic effect of DN patients and improve renal function, the mechanism may be related to the inhibition of DN patients with HIF-1α and VEGF levels.